Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials

详细信息    查看全文

• 作者：Peizhun Du ; Xuelong Jiao ; Yanbing Zhou ; Yu Li ; Shan Kang ; Dongfeng Zhang…
• 关键词：Meta ; analysis ; Differentiated thyroid cancer ; Radioiodine ; Thyroid cancer ; Ablation ; Randomized controlled trial
• 刊名：Endocrine
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：48
• 期：1
• 页码：96-105
• 全文大小：905 KB
• 参考文献：1. A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668-676 (2004). doi:10.1210/jc.2003-031167 CrossRef
  2. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS. Med. 6(7), e1000097 (2009). doi:10.1371/journal.pmed.1000097 CrossRef
  3. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011). doi:10.1136/bmj.d5928 CrossRef
  4. U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol, P.M. Clark, K. Farnell, R. McCready, J. Smellie, J.A. Franklyn, R. John, C.M. Nutting, K. Newbold, C. Lemon, G. Gerrard, A. Abdel-Hamid, J. Hardman, E. Macias, T. Roques, S. Whitaker, R. Vijayan, P. Alvarez, S. Beare, S. Forsyth, L. Kadalayil, A. Hackshaw, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366(18), 1674-685 (2012). doi:10.1056/NEJMoa1109589 CrossRef
  5. M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy, C. Bournaud, F. Bonichon, C. Dejax, M.E. Toubert, S. Leboulleux, M. Ricard, E. Benhamou, Tumeurs de la thyroide refractaires network for the essai stimulation ablation equivalence, t.: strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366(18), 1663-673 (2012). doi:10.1056/NEJMoa1108586 CrossRef
  6. Sirisalipoch, S., Buachum, V., Pasawang, P., Tepmongkol, S.: Prospective randomised trial for the evaluation of the efficacy of low vs. high dose I-131 for post operative remnant ablation in differentiated thyroid cancer. World J. Nucl. Med. 3(suppl. 1) (2004)
  7. T. Pilli, E. Brianzoni, F. Capoccetti, M.G. Castagna, S. Fattori, A. Poggiu, G. Rossi, F. Ferretti, E. Guarino, L. Burroni, A comparison of 1850 (50?mCi) and 3700?MBq (100?mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92(9), 3542-546 (2007) CrossRef
  8. M. Zaman, R. Toor, S. Kamal, M. Maqbool, S. Habib, K. Niaz, A randomized clinical trial comparing 50?mCi and 100?mCi of iodine-131 for ablation of differentiated thyroid cancers. J. Pak. Med. Assoc. 56(8), 353-56 (2006)
  9. M. Caglar, F.M. Bozkurt, C.K. Akca, S.E. Vargol, M. Bayraktar, O. Ugur, E. Karaagaoglu, Comparison of 800 and 3700?MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl. Med. Commun. 33(3), 268-74 (2012). doi:10.1097/MNM.0b013e32834ec5d6 CrossRef
  10. M. Gawkowska-Suwinska, M. Turska, J. Roskosz, Z. Puch, B. Jurecka-Tuleja, D. Handkiewicz-Junak, Z. Wygoda, B. Jarzab, Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad. Lek. 54(Suppl 1), 278-88 (2001)
  11. C. Bal, A.K. Padhy, S. Jana, G.S. Pant, A.K. Basu, Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in pat
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

It is not known whether low-dose radioiodine is as effective as high-dose radioiodine for treating patients with differentiated thyroid cancer after surgery. This study compared ablation success rates of different doses of radioiodine in patients with differentiated thyroid cancer after thyroidectomy. Fifteen randomized controlled trials were obtained from PubMed, Embase, and Cochrane Library (1966 to February 2013). Stata version 12.0 was used to pool the outcomes. Mantel–Haenszel (MH) and inverse variance (IV) methods were used in a fixed-effects and random-effects model, respectively. The relative risk (RR) with 95?% confidence interval (CI) was used to compare the success rates of different doses of radioiodine. There were a total of 3,046 patients. The pooled RR for comparing ablation success with low- and high-dose radioiodine was 0.90 (95?% CI 0.83-.98, IV). Excluding a study with a distinctive outcome, sensitivity analysis showed that the pooled RR was 0.95 (95?% CI 0.92-.99, MH). In subgroup analysis, the pooled RR of three studies that only administrated radioiodine to patients with pT2- cancer was 0.93 (95?% CI 0.83-.04, MH); the pooled RR of five studies with total thyroidectomy for all patients was 0.96 (95?% CI 0.92-.00, MH); and the pooled RR of four studies that used thyrotropin α to stimulate serum thyrotropin was 0.96 (95?% CI 0.90-.02, MH). The pooled RRs for comparing ablation success for moderate-dose versus high-dose and low-dose radioiodine were 0.94 (95?% CI 0.85-.04, IV) and 0.87 (95?% CI 0.73-.04, IV), respectively. Low-dose radioiodine can be used in patients undergoing total thyroidectomy. For those who receive insufficient surgical treatment, high-dose radioiodine is more appropriate.